STOCK TITAN
  1. Home
  2. Sec-filings
  3. OFIX
  4. [Form 4] Orthofix Medical Inc. Insider Trading Activity

Orthofix (OFIX) Form 4: Henneman Receives 18.8k Deferred Stock Units

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Orthofix Medical Inc. (OFIX) – Form 4 insider filing dated 06/23/2025

Director John B. Henneman III reported a single equity-compensation transaction that occurred on 06/18/2025.

  • Securities granted: 18,841 deferred stock units (DSUs) coded “A” (award).
  • Price: $0, confirming the grant was part of the company’s director compensation plan rather than an open-market purchase or sale.
  • Vesting schedule: DSUs vest 100 % on the first anniversary of the grant provided the director continues in service. Each DSU converts into one share of common stock within 45 days after the director’s service ends.
  • Post-transaction beneficial ownership: 83,706 OFIX common shares, comprising the newly granted 18,841 DSUs, 29,506 previously reported DSUs, and 951 shares acquired under the Orthofix Stock Purchase Plan on 04/30/2025.
  • The filing was executed by attorney-in-fact J. Andres Cedron and submitted on 06/23/2025.

No derivative securities were reported in Table II, and the filing indicates a single reporting person with director status. The form contains no indication of a 10b5-1 trading plan and no amendments to earlier filings.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Director received 18,841 DSUs; ownership now 83,706 shares—routine compensation, neutral market impact.

This Form 4 reflects a standard annual equity grant to non-employee director John B. Henneman III. The award increases his notional stake by roughly 29 % (18,841 ÷ 64,865 prior shares) without cash consideration, signaling continued board-level equity alignment but creating only immaterial share dilution. Vesting is time-based, a typical structure encouraging board retention. No open-market buying or selling occurred; consequently, the filing does not convey a directional view on valuation. With no derivatives, no multi-party filings, and no 10b5-1 notation, the disclosure is administrative. Investors should view the transaction as routine and non-impactful to near-term price dynamics.

Insider HENNEMAN JOHN B III
Role Director
Type Security Shares Price Value
Grant/Award Common Stock 18,841 $0.00 --
Holdings After Transaction: Common Stock — 83,706 shares (Direct)
Footnotes (1)
  1. Represents an award of deferred stock units that vest in full on the first anniversary of the grant date, subject to the reporting person's service through such date. Each deferred stock unit represents a contingent right to receive one share of common stock of the issuer. Vested deferred stock units will settle and convert into common stock within 45 days of the reporting person's termination of service with the issuer. Includes 29,506 previously reported deferred stock units and 951 shares acquired under Orthofix's Stock Purchase Plan on 4/30/2025.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
HENNEMAN JOHN B III
(Last) (First) (Middle)
3451 PLANO PARKWAY
(Street)
LEWISVILLE TX 75056
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Orthofix Medical Inc. [ OFIX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/18/2025 A 18,841(1) A $0 83,706(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents an award of deferred stock units that vest in full on the first anniversary of the grant date, subject to the reporting person's service through such date. Each deferred stock unit represents a contingent right to receive one share of common stock of the issuer. Vested deferred stock units will settle and convert into common stock within 45 days of the reporting person's termination of service with the issuer.
2. Includes 29,506 previously reported deferred stock units and 951 shares acquired under Orthofix's Stock Purchase Plan on 4/30/2025.
/s/ J. Andres Cedron, attorney-in-fact 06/23/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

How many Orthofix (OFIX) shares did Director John B. Henneman III acquire on 06/18/2025?

18,841 deferred stock units were granted on that date.

What is the vesting schedule for the 18,841 DSUs granted to the OFIX director?

They vest in full one year after the 06/18/2025 grant date, subject to continued board service.

What is Director Henneman's total beneficial ownership in OFIX after the reported grant?

He now holds 83,706 shares (including DSUs and 951 shares from the 04/30/2025 stock purchase plan).

Did the OFIX Form 4 filing report any open-market purchases or sales?

No. The only transaction disclosed was a zero-cost equity award; no purchases or sales were reported.

Were any derivative securities included in the OFIX insider filing?

No derivative positions were reported in Table II of the Form 4.